drugset
drugset / Trial / NCT04839926

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

NCT04839926 ↗

Phase 1 Unknown 60 enrolled Jiangsu Nhwa Pharmaceutical Co., Ltd.
RandomizedSequentialTriple-blindBasic science

Summary

The primary objective of single ascending dose study is to evaluate the safety and tolerability of CY150112 after single oral administration of different doses in healthy Chinese subjects.

Timeline

Start
2021-03-02
Primary completion
2021-08-01
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CY150112 Unknown 0.5 mg Oral
Subject CY150112 Unknown 1.5 mg Oral
Subject CY150112 Unknown 4.5 mg Oral
Subject CY150112 Unknown 10 mg Oral
Subject CY150112 Unknown 18 mg Oral
Subject CY150112 Unknown 24 mg Oral

Indications

schizophrenia